Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
MeiraGTx Holdings plc MGTX
$5.77
-$0.06 (-1.03%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
286511232.00000000
-
week52high
11.58
-
week52low
4.77
-
Revenue
15920000
-
P/E TTM
-2
-
Beta
1.38085600
-
EPS
-2.81000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | Buy | 12 авг 2022 г. |
| Chardan Capital | Buy | Buy | 13 мая 2022 г. |
| Barclays | Overweight | Overweight | 13 мая 2022 г. |
| RBC Capital | Outperform | 23 окт 2020 г. | |
| B of A Securities | Buy | Buy | 15 сент 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Wollin Robert J | D | 10000 | 10000 | 14 янв 2023 г. |
| Wollin Robert J | D | 5712 | 5288 | 14 янв 2023 г. |
| Wollin Robert J | A | 11000 | 10000 | 14 янв 2023 г. |
| Zeldin Robert K | D | 75000 | 75000 | 14 янв 2023 г. |
| Zeldin Robert K | D | 50487 | 29513 | 14 янв 2023 г. |
| Zeldin Robert K | A | 80000 | 75000 | 14 янв 2023 г. |
| Forbes Alexandria | D | 60000 | 60000 | 14 янв 2023 г. |
| Forbes Alexandria | D | 1106450 | 31726 | 14 янв 2023 г. |
| Forbes Alexandria | A | 1138176 | 60000 | 14 янв 2023 г. |
| Giroux Richard | D | 50000 | 50000 | 14 янв 2023 г. |
Новостная лента
MeiraGTx to Participate in Upcoming Investor Conferences
GlobeNewsWire
20 апр 2023 г. в 17:00
LONDON and NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
GlobeNewsWire
08 дек 2022 г. в 16:30
LONDON and NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present clinical data from the Company's AAV-hAQP1 Phase 1 AQUAx clinical trial for the treatment of radiation-induced xerostomia (RIX) on Tuesday, December 13, 2022, at 8:00 a.m. ET.
MeiraGTx to Participate in Upcoming Investor Conferences
GlobeNewsWire
22 ноя 2022 г. в 16:30
LONDON and NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:
MeiraGTx to Participate in Upcoming Investor Conferences
GlobeNewsWire
08 сент 2022 г. в 16:30
LONDON and NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
11 авг 2022 г. в 11:18
MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -31.03% and 14.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?